A Open-label, Randomized Study to Evaluate the Safety and Tolerability of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) Administered to Participants With Different Immunization Schedules

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The Phase 1 clinical trial of the freeze-dried human rabies vaccine (human diploid cells) will be conducted on participants aged 10 to 60. This study will design a single-arm, randomized, open-access trial with different immunization schedules (5-dose schedule and 2-1-1 schedule) to evaluate the safety and tolerability of the vaccine in participants aged 10 to 60

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 60
Healthy Volunteers: t
View:

• (1) The participants' ages range from 10 to 60 years old (≥10 years old and \<61 years old).

• (2) Participants aged 10 to 17 and their guardians can provide valid identification documents, and participants aged 18 to 60 can provide their own valid identification documents.

• (3) Participants aged 10 to 17 and their guardians, as well as participants aged 18 to 60, can sign the informed consent form voluntarily to participate in the trial, fully understand the trial procedures, the risks of participating in the trial, and other intervention measures that can be chosen if they do not participate in the trial, etc.

• (4) Possess basic reading and writing skills, and be capable of reading, understanding and filling in diary cards and contact cards; (5) Female participants with fertility must also meet the following conditions: 1) They have taken effective contraceptive measures within two weeks prior to participating in this trial; 2) Have no plans to have children within 6 months from the start of participating in this trial until the full vaccination. 3) Understand and agree to take effective contraceptive measures during the trial period (from the first dose to within 6 months after the full vaccination). Effective contraceptive measures include: condoms (for men), intrauterine devices, oral contraceptives (excluding emergency contraceptives), sterilization, abstention, injection or implantable contraception, sustained-release local contraceptives, hormone patches, diaphragms, cervical caps, etc. External ejaculation and safe period contraception are not regarded as effective contraceptive measures.

Locations
Other Locations
China
Henan Provincial Center for Disease Control and Prevention
RECRUITING
Zhengzhou
Contact Information
Primary
Zhiqiang Q Xie
xiezqshang@163.com
+8613526534586
Time Frame
Start Date: 2025-05-23
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 60
Treatments
Experimental: Group1
The Participants received 1 dose of AIM2301 on day 0, 3, 7, 14 and 28, a total of 5 doses
Experimental: Group2
The Participants received 2 dose of AIM2301 on day 0, 1 dose of AIM2301 on day7 and 21, a total of 4 doses
Related Therapeutic Areas
Sponsors
Leads: Ningbo Rongan Biological Pharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov